Division of Diabetes and Endocrinology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, 6701 Fannin St. Ste 1020, Houston, TX, 77030, USA.
Division of Endocrinology, Department of Pediatrics, Harbor-UCLA Medical Center, The Lundquist Institute of Biomedical Innovation at Harbor-UCLA, Torrance, CA, 90509, USA.
Curr Atheroscler Rep. 2023 Aug;25(8):495-507. doi: 10.1007/s11883-023-01122-1. Epub 2023 Jul 31.
PURPOSE OF REVIEW: The goal of this article is to review algorithms for treating dyslipidemia in youth, discuss pitfalls, propose enhanced algorithms to address pitfalls, and consider future directions. RECENT FINDINGS: The presence of modifiable and non-modifiable cardiovascular disease (CVD) risk factors during childhood is associated with CVD-related events in adulthood. Recent data has shown that childhood initiation of statin therapy in youth < 18 years of age with familial hypercholesterolemia reduces the risk of adult CVD. However, pediatric dyslipidemia remains undertreated in part due to a lack of primary health care providers with adequate understanding of screening guidelines and pediatric lipidologists with experience in treatment and follow-up of this unique population. Management algorithms have been published by the National Heart, Lung, and Blood Institute and American Heart Association as tools to empower clinicians to manage dyslipidemia. We propose enhanced algorithms, which incorporate recently approved pharmacotherapy to address the management gaps. Future algorithms based upon clinical risk scores may enhance treatment and improve outcomes. Algorithms for dyslipidemia management which target youth < 18 years of age are tools which empower clinicians to manage dyslipidemia in this unique population. Enhanced algorithms may help address pitfalls. We acknowledge the need for further risk assessment tools in pediatrics for tailored dyslipidemia management.
目的综述:本文旨在综述青少年血脂异常的治疗方法,讨论其中的陷阱,提出改进的方法以克服这些陷阱,并探讨未来的发展方向。
最近的发现:儿童时期存在可改变和不可改变的心血管疾病(CVD)危险因素与成年期的 CVD 相关事件有关。最近的数据表明,在患有家族性高胆固醇血症的 18 岁以下青少年中,早期开始使用他汀类药物治疗可以降低成年期 CVD 的风险。然而,儿科血脂异常的治疗仍然不足,部分原因是缺乏对筛查指南有充分了解的初级保健提供者,以及在治疗和随访这一独特人群方面经验丰富的儿科脂质专家。美国国立心肺血液研究所和美国心脏协会已经发布了管理算法,作为赋予临床医生管理血脂异常能力的工具。我们提出了改进的算法,纳入了最近批准的药物治疗方法,以解决管理中的差距。基于临床风险评分的未来算法可能会改善治疗效果并改善预后。针对 18 岁以下青少年的血脂异常管理算法是赋予临床医生在这一独特人群中管理血脂异常能力的工具。改进的算法可能有助于克服陷阱。我们认识到需要在儿科领域进一步开发风险评估工具,以进行针对性的血脂异常管理。
Curr Atheroscler Rep. 2023-8
J Clin Endocrinol Metab. 2019-10-1
Curr Opin Endocrinol Diabetes Obes. 2023-2-1
Endocrinol Metab Clin North Am. 2022-9
Clin Gastroenterol Hepatol. 2014-7
J Clin Endocrinol Metab. 2014-9
J Pediatr Endocrinol Metab. 2025-5-6
Medicina (Kaunas). 2024-9-29
Curr Atheroscler Rep. 2024-12
Curr Atheroscler Rep. 2024-12
Curr Opin Endocrinol Diabetes Obes. 2023-2-1
Diabetes Care. 2023-1-1
Curr Atheroscler Rep. 2022-6
N Engl J Med. 2022-5-19
Curr Atheroscler Rep. 2022-5
Eur Heart J. 2022-8-7
N Engl J Med. 2020-8-20